cancer vaccine by fusions of dendritic and cancer cells癌症疫苗的树突和癌症细胞的融合.pdfVIP

Hindawi Publishing Corporation Clinical and Developmental Immunology Volume 2009, Article ID 657369, 13 pages doi:10.1155/2009/657369 Review Article Cancer Vaccine by Fusions of Dendritic and Cancer Cells Shigeo Koido,1, 2, 3 Eiichi Hara,4 Sadamu Homma,3 Yoshihisa Namiki,2 Toshifumi Ohkusa,1 Jianlin Gong,5 and Hisao Tajiri1 1 Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo 277-8567, Japan 2 Institute of Clinical Medicine and Research, The Jikei University School of Medicine, Tokyo 277-8567, Japan 3 Department of Oncology, Institute of DNA Medicine, The Jikei University School of Medicine, Tokyo 277-8567, Japan 4 Saitama Cancer Center Research Institute for Clinical Oncology, Saitama 277-8567, Japan 5 Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA Correspondence should be addressed to Shigeo Koido, shigeo koido@jikei.ac.jp Received 17 October 2009; Accepted 9 December 2009 Recommended by Mario Clerici Dendritic cells (DCs) are potent antigen-presenting cells and play a central role in the initiation and regulation of primary immune responses. Therefore, their use for the active immunotherapy against cancers has been studied with considerable interest. The fusion of DCs with whole tumor cells represents in many ways an ideal approach to deliver, process, and subsequently present a broad array of tumor-associated antigens, including those yet to be unidentified, in the context of DCs-derived costimulatory molecules. DCs/tumor fusion vaccine stimulates potent antitumor immunity in the animal tumor models. In the human studies, T cells stimulated by DC/tumor fusion cells are effective in lysis of tumor cells that are used as the fusion partner. In the